NZ612673A - Methods and composition for diagnosis and prognosis of renal injury and renal failure - Google Patents

Methods and composition for diagnosis and prognosis of renal injury and renal failure

Info

Publication number
NZ612673A
NZ612673A NZ612673A NZ61267310A NZ612673A NZ 612673 A NZ612673 A NZ 612673A NZ 612673 A NZ612673 A NZ 612673A NZ 61267310 A NZ61267310 A NZ 61267310A NZ 612673 A NZ612673 A NZ 612673A
Authority
NZ
New Zealand
Prior art keywords
event
measured concentration
threshold
likelihood
renal
Prior art date
Application number
NZ612673A
Other languages
English (en)
Inventor
Paul Mcpherson
Joseph Anderberg
Jeff Gray
James Patrick Kampf
Kevin Nakamura
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of NZ612673A publication Critical patent/NZ612673A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors
    • G01N2333/7452Thrombomodulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81Protease inhibitors
    • G01N2333/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ612673A 2009-09-18 2010-09-17 Methods and composition for diagnosis and prognosis of renal injury and renal failure NZ612673A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24400009P 2009-09-18 2009-09-18
US24399509P 2009-09-18 2009-09-18
US25463609P 2009-10-23 2009-10-23
NZ598741A NZ598741A (en) 2009-09-18 2010-09-17 Methods and composition for diagnosis and prognosis of renal injury and renal failure by performing assays to detect metalloproteinase inhibitor 4 on a body fluid sample

Publications (1)

Publication Number Publication Date
NZ612673A true NZ612673A (en) 2014-10-31

Family

ID=43759017

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ612673A NZ612673A (en) 2009-09-18 2010-09-17 Methods and composition for diagnosis and prognosis of renal injury and renal failure
NZ598741A NZ598741A (en) 2009-09-18 2010-09-17 Methods and composition for diagnosis and prognosis of renal injury and renal failure by performing assays to detect metalloproteinase inhibitor 4 on a body fluid sample

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ598741A NZ598741A (en) 2009-09-18 2010-09-17 Methods and composition for diagnosis and prognosis of renal injury and renal failure by performing assays to detect metalloproteinase inhibitor 4 on a body fluid sample

Country Status (10)

Country Link
US (2) US20130045494A1 (enExample)
EP (2) EP3299821A1 (enExample)
JP (3) JP2013513086A (enExample)
CN (2) CN102576012B (enExample)
AU (2) AU2010295512B2 (enExample)
CA (1) CA2773905A1 (enExample)
EA (1) EA201290106A1 (enExample)
MX (1) MX2012003168A (enExample)
NZ (2) NZ612673A (enExample)
WO (1) WO2011035097A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2748605T (pt) * 2011-08-26 2019-05-03 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
EP3025263A2 (en) * 2013-07-26 2016-06-01 Koninklijke Philips N.V. Computerization and visualization of clinical rules and definitions for patient monitoring systems.
GB201501597D0 (en) * 2015-01-30 2015-03-18 Randox Lab Ltd Thrombomodulin
CN108271422A (zh) 2015-06-25 2018-07-10 株式会社国际电气通信基础技术研究所 基于器官间串扰系统的预测装置及预测程序
EP3410119B1 (en) * 2016-01-29 2021-03-17 Karydo Therapeutix, Inc. Renal function evaluating device, device for predicting onset of kidney disease complications, and phosphorous ingestion amount estimating device
EP4005598A1 (en) 2016-03-29 2022-06-01 Karydo Therapeutix, Inc. Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure
CN109414504B (zh) 2016-03-29 2022-04-08 无限生物制药公司 药物组合物或食品组合物及评价活性成分体内效果的方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
JPH0736019B2 (ja) * 1989-12-27 1995-04-19 富士薬品工業株式会社 新規な抗ヒトトロンボモジュリンモノクローナル抗体によるヒトトロンボモジュリンおよびその分解産物の定量方法
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
ATE177841T1 (de) 1991-04-10 1999-04-15 Biosite Diagnostics Inc ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
CA2107899A1 (en) 1991-04-10 1992-10-11 Gunars Edwin Valkirs Novel conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
CN1495258A (zh) * 1994-12-13 2004-05-12 人体基因组科学有限公司 金属蛋白酶-4的人组织抑制剂
US6544761B2 (en) * 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
CN1129666C (zh) * 1994-12-13 2003-12-03 人体基因组科学有限公司 金属蛋白酶-4的人组织抑制剂
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AU2094101A (en) * 1999-12-13 2001-06-18 Duanqing Pei Leukolysin/mmp25/mt6-mmp
EP2339035A1 (en) * 2000-12-07 2011-06-29 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
JP4179988B2 (ja) * 2001-07-12 2008-11-12 協和メデックス株式会社 変性リポ蛋白質の定量法、変性リポ蛋白質の定量用試薬、循環器疾患の検出方法および循環器疾患の検出試薬
EP1742650A1 (en) * 2004-03-30 2007-01-17 Den Kgl.Veterin R-Og Landboh Jskole Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
US7713693B1 (en) * 2004-09-01 2010-05-11 University Of Louisiana At Monroe Human cancer cell specific gene transcript
US20060160112A1 (en) * 2004-12-02 2006-07-20 Erdal Cavusoglu Tissue inhibitor of metalloproteinase (TIMP) as a marker and predictor of cardiovascular disease and both cardiac and non-cardiac mortality
US20090178145A1 (en) * 2005-05-11 2009-07-09 The Procter & Gamble Company Methods and targets for identifying compounds for regulating angiogenesis
WO2007053610A2 (en) * 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
JP2007163151A (ja) * 2005-12-09 2007-06-28 Kitasato Gakuen 対象生物の生理状態を判定する方法
CA2651847A1 (en) * 2006-05-09 2007-11-22 Musc Foundation For Research Development Detecting diastolic heart failure by protease and protease inhibitor plasma profiling
CN101490273A (zh) * 2006-05-09 2009-07-22 南卡罗来纳州医科大学研究发展基金会 利用蛋白酶和蛋白酶抑制剂血浆分析检测舒张期心力衰竭
WO2008084331A2 (en) * 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
JP2009544013A (ja) * 2006-07-11 2009-12-10 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント プロテアーゼおよびプロテアーゼ阻害因子のプロファイリングによる心筋梗塞後の心不全の予測
GB0617429D0 (en) * 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
US7842472B2 (en) * 2006-11-14 2010-11-30 Alere International Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
FR2909180B1 (fr) * 2006-11-29 2009-02-20 Diagnostica Stago Soc Par Acti Methode de mesure fonctionnelle de l'activite de la thrombomoduline plasmatique.

Also Published As

Publication number Publication date
CN105004864A (zh) 2015-10-28
AU2010295512B2 (en) 2014-12-18
EP2470904A4 (en) 2013-05-01
MX2012003168A (es) 2012-05-08
AU2010295512A1 (en) 2012-04-05
JP2013513086A (ja) 2013-04-18
JP6403712B2 (ja) 2018-10-10
AU2015200953A1 (en) 2015-03-12
NZ598741A (en) 2013-07-26
HK1167889A1 (zh) 2012-12-14
CN105004864B (zh) 2017-11-03
CN102576012A (zh) 2012-07-11
CN102576012B (zh) 2015-07-15
HK1212774A1 (zh) 2016-06-17
US20130045494A1 (en) 2013-02-21
WO2011035097A1 (en) 2011-03-24
JP2015129764A (ja) 2015-07-16
EP2470904A1 (en) 2012-07-04
EP3299821A1 (en) 2018-03-28
US20190250170A1 (en) 2019-08-15
JP2016176953A (ja) 2016-10-06
CA2773905A1 (en) 2011-03-24
EA201290106A1 (ru) 2012-12-28

Similar Documents

Publication Publication Date Title
NZ700695A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ594771A (en) Methods and compositions for diagnosis and prognosis of renal injury and failure
NZ625423A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ624609A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ701807A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ606124A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ628843A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ592365A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ610356A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ600160A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ604873A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ594772A (en) Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c
NZ630277A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ608384A (en) Biomarkers of renal injury
NZ630621A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ598034A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ628085A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ598741A (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure by performing assays to detect metalloproteinase inhibitor 4 on a body fluid sample
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
WO2010096154A3 (en) Compositions and methods for diagnosis and prognosis of colorectal cancer
IN2014CN01787A (enExample)
TR201903235T4 (tr) Böbrek hasari ve böbrek yetmezli̇ği̇ni̇n tanilanmasi ve prognozuna yöneli̇k metotlar ve bi̇leşi̇mler.
NZ601648A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 SEP 2017 BY FB RICE

Effective date: 20150203

LAPS Patent lapsed